ATE290877T1 - Stabilisierte insulin-zubereitungen - Google Patents

Stabilisierte insulin-zubereitungen

Info

Publication number: ATE290877T1
Authority: AT; Austria
Prior art keywords: insulin preparations; stabilized insulin; glycylglycine; analogue; citrate
Prior art date: 1998-01-09

Application number

AT99900206T

Other languages

English (en)

Inventor

Peter Langballe

Elsebeth Norup

Original Assignee

Novo Nordisk As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-01-09

Filing date

1999-01-06

Publication date

2005-04-15

1999-01-06 Application filed by Novo Nordisk As filed Critical Novo Nordisk As

2005-04-15 Application granted granted Critical

2005-04-15 Publication of ATE290877T1 publication Critical patent/ATE290877T1/de

Links

NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title abstract 4
102000004877 Insulin Human genes 0.000 title abstract 2
108090001061 Insulin Proteins 0.000 title abstract 2
229940125396 insulin Drugs 0.000 title abstract 2
238000002360 preparation method Methods 0.000 title 1
YMAWOPBAYDPSLA-UHFFFAOYSA-N glycylglycine Chemical compound [NH3+]CC(=O)NCC([O-])=O YMAWOPBAYDPSLA-UHFFFAOYSA-N 0.000 abstract 4
108010008488 Glycylglycine Proteins 0.000 abstract 2
229940043257 glycylglycine Drugs 0.000 abstract 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 abstract 1
101000976075 Homo sapiens Insulin Proteins 0.000 abstract 1
JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 abstract 1
239000007983 Tris buffer Substances 0.000 abstract 1
239000000872 buffer Substances 0.000 abstract 1
239000011575 calcium Substances 0.000 abstract 1
229910001424 calcium ion Inorganic materials 0.000 abstract 1
PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 abstract 1
229910001425 magnesium ion Inorganic materials 0.000 abstract 1
229910021645 metal ion Inorganic materials 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
239000000126 substance Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Diabetes (AREA)
Oil, Petroleum & Natural Gas (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Bioinformatics & Cheminformatics (AREA)
Endocrinology (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Immunology (AREA)
Inorganic Chemistry (AREA)
Dermatology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Obesity (AREA)
Hematology (AREA)
Emergency Medicine (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

AT99900206T 1998-01-09 1999-01-06 Stabilisierte insulin-zubereitungen ATE290877T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP98610001		1998-01-09
PCT/DK1999/000006 WO1999034821A1 (en)	1998-01-09	1999-01-06	Stabilised insulin compositions

Publications (1)

Publication Number	Publication Date
ATE290877T1 true ATE290877T1 (de)	2005-04-15

Family

ID=8235844

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT99900206T ATE290877T1 (de)	1998-01-09	1999-01-06	Stabilisierte insulin-zubereitungen

Country Status (7)

Country	Link
US (1)	US6174856B1 (de)
EP (1)	EP1044016B1 (de)
JP (1)	JP2002500196A (de)
AT (1)	ATE290877T1 (de)
AU (1)	AU1870099A (de)
DE (1)	DE69924232D1 (de)
WO (1)	WO1999034821A1 (de)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ZA984697B (en)	1997-06-13	1999-12-01	Lilly Co Eli	Stable insulin formulations.
US20020155994A1 (en) *	1997-10-24	2002-10-24	Svend Havelund	Aggregates of human insulin derivatives
ES2180511T3 (es) *	1999-01-26	2003-02-16	Lilly Co Eli	Formulaciones monodispersas de analogos de insulina acilados hexamericos.
AU2001220765A1 (en)	2000-01-24	2001-07-31	Medtronic Minimed, Inc.	Mixed buffer system for stabilizing polypeptide formulations
AUPQ633900A0 (en)	2000-03-20	2000-04-15	Jurox Pty Ltd	Anaesthetic composition
US20030148924A1 (en) *	2002-07-09	2003-08-07	Tamar Tennenbaum	Methods and pharmaceutical compositions of healing wounds
US20100129332A1 (en) *	2000-07-31	2010-05-27	Tamar Tennenbaum	Methods and pharmaceutical compositions for healing wounds
US20060258562A1 (en) *	2000-07-31	2006-11-16	Healor Ltd.	Methods and pharmaceutical compositions for healing wounds
US20040037828A1 (en)	2002-07-09	2004-02-26	Bar-Ilan University	Methods and pharmaceutical compositions for healing wounds
WO2002009639A2 (en) *	2000-07-31	2002-02-07	Bar Ilan University	Methods and pharmaceutical compositions for healing wounds
DE10114178A1 (de)	2001-03-23	2002-10-10	Aventis Pharma Gmbh	Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
US6737401B2 (en)	2001-06-28	2004-05-18	Metronic Minimed, Inc.	Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom
US20030158670A1 (en) *	2001-12-04	2003-08-21	Philip Hougaard	Method of planning and performing stability studies
AU2003208316A1 (en) *	2002-03-13	2003-09-22	Novo Nordisk A/S	Minimising body weight gain in insulin treatment
AU2003218635A1 (en) *	2002-05-07	2003-11-11	Novo Nordisk A/S	Soluble formulations comprising insulin aspart and insulin detemir
DE10227232A1 (de) *	2002-06-18	2004-01-15	Aventis Pharma Deutschland Gmbh	Saure Insulinzubereitungen mit verbesserter Stabilität
US20040126831A1 (en) *	2002-12-31	2004-07-01	Medtronic Minimed, Inc.	Functionalization of immobilized proteins
KR101159559B1 (ko) *	2003-08-05	2012-06-26	노보 노르디스크 에이/에스	신규의 인슐린 유도체
WO2005013885A2 (en)	2003-08-07	2005-02-17	Healor Ltd.	Pharmaceutical compositions and methods for accelerating wound healing
MX2007000883A (es)	2004-07-19	2007-04-02	Biocon Ltd	Conjugados de insulina-oligomero, formulaciones y usos de los mismos.
JP4874989B2 (ja)	2004-11-22	2012-02-15	ノヴォノルディスクアー／エス	可溶性で安定なインスリン含有調合物
EP2256130B1 (de)	2005-02-02	2013-09-25	Novo Nordisk A/S	Neuartige Insulinderivate
EP2452687A3 (de)	2005-08-29	2012-09-05	HealOr Ltd.	Verfahren und Zusammensetzungen zur Vorbeugung und Behandlung von diabetischer und alternder Haut
US20090074882A1 (en)	2005-12-28	2009-03-19	Novo Nordisk A/S	Insulin compositions and method of making a composition
DE602007009496D1 (de) *	2006-02-27	2010-11-11	Novo Nordisk As	Insulinderivate
EP2015770B1 (de) *	2006-05-09	2012-09-26	Novo Nordisk A/S	Insulinderivate
US8796205B2 (en) *	2006-05-09	2014-08-05	Novo Nordisk A/S	Insulin derivative
WO2008152106A1 (en)	2007-06-13	2008-12-18	Novo Nordisk A/S	Pharmaceutical formulation comprising an insulin derivative
CN101835486B (zh) *	2007-07-30	2012-12-12	希尔洛有限公司	用于治疗创伤的药物组合物以及相关方法
BRPI0818004B8 (pt) *	2007-10-16	2021-05-25	Biocon Ltd	composição farmacêutica sólida administrável por via oral e o processo da mesma.
WO2009060071A1 (en) *	2007-11-08	2009-05-14	Novo Nordisk A/S	Insulin derivative
PL2229407T3 (pl)	2008-01-09	2017-06-30	Sanofi-Aventis Deutschland Gmbh	Nowe pochodne insuliny o ekstremalnie spowolnionym profilu czasu działania
EP2113564A1 (de) *	2008-05-01	2009-11-04	Arecor Limited	Proteinformulierung
TWI451876B (zh) *	2008-06-13	2014-09-11	Lilly Co Eli	聚乙二醇化之離脯胰島素化合物
FR2932908B1 (fr) *	2008-06-24	2012-11-16	Arjowiggins Licensing Sas	Structure comportant un filigrane ou pseudo-filigrane et un dispositif a microcircuit integre.
EP3228320B1 (de)	2008-10-17	2019-12-18	Sanofi-Aventis Deutschland GmbH	Kombination von einem insulin und einem glp-1-agonisten
CA2738615A1 (en) *	2008-10-30	2010-05-06	Novo Nordisk A/S	Treating diabetes melitus using insulin injections with less than daily injection frequency
US8940690B2 (en)	2009-01-28	2015-01-27	National Institutes Of Health (Nih)	Synthetic conjugates and uses thereof
US9050370B2 (en)	2009-01-28	2015-06-09	Smartcells, Inc.	Conjugate based systems for controlled drug delivery
US9060927B2 (en)	2009-03-03	2015-06-23	Biodel Inc.	Insulin formulations for rapid uptake
WO2010107519A1 (en)	2009-03-20	2010-09-23	Smartcells, Inc.	Terminally-functionalized conjugates and uses thereof
FR2943538B1 (fr)	2009-03-27	2011-05-20	Adocia	Formulation a action rapide d'insuline recombinante humaine
US9018190B2 (en)	2009-03-27	2015-04-28	Adocia	Functionalized oligosaccharides
EP3202394A1 (de) *	2009-07-06	2017-08-09	Sanofi-Aventis Deutschland GmbH	Wässrige insulinzubereitungen enthaltend methionin
US20110097363A1 (en) *	2009-10-22	2011-04-28	Cpex Pharmaceuticals, Inc.	Therapeutically Effective Preparations of Insulin
PE20121316A1 (es)	2009-11-13	2012-10-05	Sanofi Aventis Deutschland	Composicion farmaceutica que comprende un agonista de glp-1 y metionina
PT2554183T (pt)	2009-11-13	2018-07-09	Sanofi Aventis Deutschland	Composição farmacêutica que compreende um agonista de glp-1, uma insulina e metionina
JP2013516500A (ja)	2010-01-11	2013-05-13	ヒールオア・リミテッド	炎症性疾患および障害を治療するための方法
US20120178675A1 (en) *	2010-07-07	2012-07-12	Biodel Inc.	Compositions And Methods For Modulating The Pharmacokinetics and Pharmacodynamics of Insulin
US20140148384A1 (en)	2010-08-30	2014-05-29	Sanofi-Aventis Deutschland Gmbh	Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
JP6049625B2 (ja)	2010-10-27	2016-12-21	ノヴォノルディスクアー／エス	様々な注射間隔を用いて施されるインスリン注射を使用する、真性糖尿病の治療
US9821032B2 (en)	2011-05-13	2017-11-21	Sanofi-Aventis Deutschland Gmbh	Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
CN108079281A (zh)	2011-08-29	2018-05-29	赛诺菲-安万特德国有限公司	用于2型糖尿病患者中的血糖控制的药物组合
TWI559929B (en)	2011-09-01	2016-12-01	Sanofi Aventis Deutschland	Pharmaceutical composition for use in the treatment of a neurodegenerative disease
US20130231281A1 (en)	2011-11-02	2013-09-05	Adocia	Rapid acting insulin formulation comprising an oligosaccharide
US9381247B2 (en) *	2012-04-16	2016-07-05	Biodel Inc.	Magnesium compositions for modulating the pharmacokinetics and pharmacodynamics of insulin and insulin analogs, and injection site pain
KR20150082640A (ko)	2012-11-13	2015-07-15	아도시아	치환된 음이온성 화합물을 포함하는 속효성 인슐린 제형
JP6735561B2 (ja)	2012-12-03	2020-08-05	メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋＳｈａｒｐ＆ＤｏｈｍｅＣｏｒｐ．	Ｏ−グリコシル化カルボキシ末端部分（ｃｔｐ）ペプチド系のインスリンおよびインスリン類似体
MX360420B (es)	2012-12-19	2018-10-31	Wockhardt Ltd	Una composicion acuosa estable que comprende insulina humana o un analogo o derivado de la misma.
MX2015006997A (es)	2012-12-26	2015-09-23	Wockhardt Ltd	Composicion farmaceutica.
WO2014177623A1 (en)	2013-04-30	2014-11-06	Novo Nordisk A/S	Novel administration regime
AR099569A1 (es)	2014-02-28	2016-08-03	Novo Nordisk As	Derivados de insulina y los usos médicos de estos
FR3020947B1 (fr)	2014-05-14	2018-08-31	Adocia	Composition aqueuse comprenant au moins une proteine et un agent solubilisant, sa preparation et ses utilisations
US9795678B2 (en)	2014-05-14	2017-10-24	Adocia	Fast-acting insulin composition comprising a substituted anionic compound and a polyanionic compound
TWI758239B (zh)	2014-12-12	2022-03-21	德商賽諾菲阿凡提斯德意志有限公司	甘精胰島素/利司那肽固定比率配製劑
TW201630622A (zh)	2014-12-16	2016-09-01	美國禮來大藥廠	速效胰島素組合物
CN107530372A (zh) *	2015-02-25	2018-01-02	当斯生物制药有限公司	液体胰岛素制剂及与其相关的方法
TWI748945B (zh)	2015-03-13	2021-12-11	德商賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患治療
TW201705975A (zh)	2015-03-18	2017-02-16	賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患之治療
JO3749B1 (ar) *	2015-08-27	2021-01-31	Lilly Co Eli	تركيبات إنسولين سريعة المفعول
FR3043557B1 (fr)	2015-11-16	2019-05-31	Adocia	Composition a action rapide d'insuline comprenant un citrate substitue
GB201607918D0 (en)	2016-05-06	2016-06-22	Arecor Ltd	Novel formulations
AU2017334290B2 (en)	2016-09-29	2023-04-20	Arecor Limited	Novel formulations
WO2018222787A1 (en)	2017-06-01	2018-12-06	Eli Lilly And Company	Rapid-acting insulin compositions
US11413352B2 (en)	2017-12-18	2022-08-16	Merck, Sharp & Dohme LLC	Conjugate based systems for controlled insulin delivery
WO2019125878A1 (en)	2017-12-18	2019-06-27	Merck Sharp & Dohme Corp.	Conjugate based systems for controlled insulin delivery
IL277721B2 (en)	2018-04-04	2024-03-01	Arecor Ltd	Medical infusion pump system for the delivery of an insulin compound
US10335464B1 (en)	2018-06-26	2019-07-02	Novo Nordisk A/S	Device for titrating basal insulin
CN114096269B (zh)	2019-07-12	2024-06-11	诺和诺德股份有限公司	高浓度胰岛素制剂
KR20220161422A (ko)	2020-03-31	2022-12-06	프로토머 테크놀로지스 인크.	비시날 디올에 대한 선택적인 반응을 위한 접합체
PE20231948A1 (es)	2020-11-19	2023-12-05	Protomer Tech Inc	Compuestos aromaticos que contienen boro y analogos de insulina
AR129357A1 (es)	2022-05-18	2024-08-14	Protomer Tech Inc	Compuestos aromáticos que contienen boro y análogos de insulina relacionados

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU550068B2 (en)	1981-03-10	1986-02-27	Novo Nordisk A/S	Zinc insulin stabilized with calcium or magnesium salts
PH23446A (en) *	1986-10-20	1989-08-07	Novo Industri As	Peptide preparations
JP2628340B2 (ja) *	1988-05-14	1997-07-09	株式会社いかがく	血液中のインシュリン成分の安定方法
DE3827533A1 (de) *	1988-08-13	1990-02-15	Hoechst Ag	Pharmazeutische zubereitung zur behandlung des diabetes mellitus
JP2837956B2 (ja) *	1993-06-21	1998-12-16	ノボノルディスクアクティーゼルスカブ	Ａｓｐ▲上Ｂ２８▼インスリン結晶
SI0792290T1 (en) *	1993-09-17	2001-12-31	Novo Nordisk As	Acylated insulin
JP3414539B2 (ja) *	1994-05-11	2003-06-09	有限会社ドット	経鼻吸収用組成物
US5474978A (en) *	1994-06-16	1995-12-12	Eli Lilly And Company	Insulin analog formulations
PT921812E (pt) *	1996-06-20	2002-04-29	Novo Nordisk As	Preparacoes de insulina contendo um halogenuro

1999
- 1999-01-06 EP EP99900206A patent/EP1044016B1/de not_active Expired - Lifetime
- 1999-01-06 AT AT99900206T patent/ATE290877T1/de not_active IP Right Cessation
- 1999-01-06 DE DE69924232T patent/DE69924232D1/de not_active Expired - Lifetime
- 1999-01-06 WO PCT/DK1999/000006 patent/WO1999034821A1/en not_active Ceased
- 1999-01-06 AU AU18700/99A patent/AU1870099A/en not_active Abandoned
- 1999-01-06 JP JP2000527269A patent/JP2002500196A/ja active Pending
- 1999-01-07 US US09/227,053 patent/US6174856B1/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
JP2002500196A (ja)	2002-01-08
US6174856B1 (en)	2001-01-16
DE69924232D1 (de)	2005-04-21
WO1999034821A1 (en)	1999-07-15
AU1870099A (en)	1999-07-26
EP1044016A1 (de)	2000-10-18
EP1044016B1 (de)	2005-03-16

Legal Events

Date	Code	Title	Description
2005-09-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE290877T1 (de)	2005-04-15	Stabilisierte insulin-zubereitungen
DK1175149T3 (da)	2003-03-17	Desinficerende sammensætning baseret på H2O2, syrer og metaliioner
BR0112969A (pt)	2004-06-22	Método de utilização de dicetopiperazinas e composições contendo-as
BR0107811B1 (pt)	2013-03-05	composiÇço herbicida seletiva e mÉtodos de controle de plantas.
BR9911724A (pt)	2001-03-20	Ciclosporina que tem um perfil de atividade melhorado
HU9902655D0 (en)	1999-10-28	Pharmaceutical composition of hedgehog proteins and use thereof
DK1082109T3 (da)	2004-08-09	Oral formulering omfattende biguanid og en organisk syre
IL127366A0 (en)	1999-10-28	Insulin preparations containing NaCl
NO20012994L (no)	2002-12-16	Arrangement og fremgangsmåte for innholdskontroll av dataobjekter, spesieltdataobjekter i MMS-meldinger
NO20015471D0 (no)	2001-11-08	Arrangement og fremgangsmåte for innholdskontroll av dataobjekter, spesielt dataobjekter i MMS-meldinger
DE69927795D1 (en)	2006-03-02	Temperaturstabile dna polymerase aus thermoanaerobacter thermohydrosulfuricus
NO20031860L (no)	2003-06-30	Kahalalid F
MXPA03010684A (es)	2005-11-04	Peptidos y el uso de los mismos para oscurecer la piel.
DK1178726T3 (da)	2003-06-10	Vandig opløsning til konservering af væv og organer
NO20024760D0 (no)	2002-10-03	Stabil og effektiv myk, fast antiperspirant og/eller deodorant
MY128230A (en)	2007-01-31	Antifungal composition
MXPA03002875A (es)	2003-07-14	Composicion de vacuna y metodo de estabilizacion.
DK1331940T3 (da)	2006-08-14	Anvendelse af det lange pentraxin PTX3 til behandling af sygdomme forårsaget af ændret aktivering af vækstfaktoren FGF-2
MXPA03004539A (es)	2004-03-26	Luciferasas aisladas y uso de las mismas.
MY138219A (en)	2009-05-29	Biologically active peptides
HRP20000703B1 (hr)	2009-11-30	Stabilni pripravci koji sadrže levosimendan i alginsku kiselinu
BR0317119A (pt)	2005-10-25	Agente antitumor, inibidor de proliferação celular, e, análogo de 3-fenil-cinolina
DE69813833D1 (de)	2003-05-28	4-cyano-4-deformylsordarizin-derivate
ATE179075T1 (de)	1999-05-15	Stabilisierte pharmazeutische zusammensetzungen enthaltend dobutamine
ATE241979T1 (de)	2003-06-15	4-cyano-4-deformylsordarinderivate